Hao-Jie Zhu

List of Publications by Year
in descending order

87	2,911	147801 31	182427 51
papers	citations	h-index	g-index

89	89	89	3414
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transcriptional Regulation of Carboxylesterase 1 in Human Liver: Role of the Nuclear Receptor Subfamily 1 Group H Member 3 and Its Splice Isoforms. Drug Metabolism and Disposition, 2022, 50, 43-48.	3.3	0
2	Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proofâ€ofâ€Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. Clinical Pharmacology and Therapeutics, 2022, 111, 878-885.	4.7	3
3	Effects of Overexpression of Fibroblast Growth Factor 15/19 on Hepatic Drug Metabolizing Enzymes. Drug Metabolism and Disposition, 2022, 50, 468-477.	3.3	2
4	Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis. Drug Metabolism and Disposition, 2022, 50, 243-248.	3.3	1
5	Physiologically-based pharmacokinetic modeling to predict methylphenidate exposure affected by interplay among carboxylesterase 1 pharmacogenetics, drug-drug interactions, and sex. Journal of Pharmaceutical Sciences, 2022, , .	3.3	0
6	Genomeâ€Wide Association Study for the Genetic Determinants of Thiopurine Sâ€Methyltransferase Protein Expression in the Liver. FASEB Journal, 2022, 36, .	0.5	0
7	Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Clinical and Translational Science, 2021, 14, 1380-1389.	3.1	4
8	Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. ACS Pharmacology and Translational Science, 2021, 4, 870-887.	4.9	9
9	Effect of CES1 genetic variation on enalapril steadyâ€state pharmacokinetics and pharmacodynamics in healthy subjects. British Journal of Clinical Pharmacology, 2021, 87, 4691-4700.	2.4	5
10	Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters. Drug Discovery Today: Technologies, 2021, 39, 49-56.	4.0	26
11	Developing a SWATH capillary LC-MS/MS method for simultaneous therapeutic drug monitoring and untargeted metabolomics analysis of neonatal plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122865.	2.3	5
12	Intranasal lipopolysaccharide administration prevents chronic stress-induced depression- and anxiety-like behaviors in mice. Neuropharmacology, 2021, 200, 108816.	4.1	13
13	Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection. Pharmaceutics, 2021, 13, 1656.	4.5	7
14	Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions. Drug Metabolism and Disposition, 2020, 48, 31-40.	3.3	30
15	Biliary Excretionâ€“Mediated Food Effects and Prediction. AAPS Journal, 2020, 22, 124.	4.4	7
16	FRACPREDâ€2Dâ€PRM: A Fraction Prediction Algorithmâ€Assisted 2D Liquid Chromatographyâ€Based Parallel Reaction Monitoringâ€Mass Spectrometry Approach for Measuring Lowâ€Abundance Proteins in Human Plasma. Proteomics, 2020, 20, 2000175.	2.2	3
17	Genome-wide pQTL analysis of protein expression regulatory networks in the human liver. BMC Biology, 2020, 18, 97.	3.8	49
18	Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. Drug Metabolism and Disposition, 2020, 48, 230-244.	3.3	62

#	Article	IF	Citations
19	Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters. Molecules, 2020, 25, 2718.	3.8	21
20	Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-Activating Enzyme. Molecular Pharmaceutics, 2020, 17, 1706-1714.	4.6	9
21	Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. Biochemical Pharmacology, 2020, 180, 114127.	4.4	13
22	Antidepressive properties of microglial stimulation in a mouse model of depression induced by chronic unpredictable stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109931.	4.8	28
23	Acetaminophen-Induced Liver Injury Alters Expression and Activities of Cytochrome P450 Enzymes in an Age-Dependent Manner in Mouse Liver. Drug Metabolism and Disposition, 2020, 48, 326-336.	3.3	25
24	Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability. Drug Metabolism and Disposition, 2019, 47, 1314-1324.	3.3	24
25	Label-free absolute protein quantification with data-independent acquisition. Journal of Proteomics, 2019, 200, 51-59.	2.4	60
26	Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver. Molecular Pharmacology, 2019, 96, 674-682.	2.3	6
27	Response to the Comments on â€œDetermining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Proteomics Methodâ€• Journal of Proteome Research, 2019, 18, 1458-1459.	3.7	0
28	Functional Study of Carboxylesterase 1 Protein Isoforms. Proteomics, 2019, 19, e1800288.	2.2	13
29	Crataegus Special Extract WS 1442 Effects on eNOS and microRNA 155. Planta Medica, 2018, 84, 1094-1100.	1.3	4
30	Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics, 2018, 33, 133-140.	2.2	42
31	A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of valacyclovir and its metabolite acyclovir in mouse and human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1092, 447-452.	2.3	9
32	Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method. Journal of Proteome Research, 2018, 17, 3606-3612.	3.7	20
33	Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. Biochemical Pharmacology, 2018, 156, 147-156.	4.4	4
34	Consequences of Phenytoin Exposure on Hepatic Cytochrome P450 Expression during Postnatal Liver Maturation in Mice. Drug Metabolism and Disposition, 2018, 46, 1241-1250.	3.3	7
35	Shortâ€•and Longâ€•term Effects of Phenytoin Exposure on the Liver Proteome of Neonatal and Adult Mice Using SWATHâ€MS Technology. FASEB Journal, 2018, 32, 563.2.	0.5	0
36	Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study. Biochemical Pharmacology, 2017, 131, 89-97.	4.4	21

#	Article	IF	Citations
37	Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2017, 37, 419-428.	1.4	16
38	A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms. Drug Metabolism and Disposition, 2017, 45, 1149-1155.	3.3	24
39	Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. Pharmacogenomics, 2017, 18, .	1.3	2
40	Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled fullâ€length protein calibrators (TAQSI). Rapid Communications in Mass Spectrometry, 2016, 30, 553-561.	1.5	24
41	Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenetics and Genomics, 2016, 26, 197-207.	1.5	18
42	Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochemical Pharmacology, 2016, 119, 76-84.	4.4	72
43	Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 555-561.	2.5	33
44	Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metabolism and Disposition, 2016, 44, 554-559.	3.3	54
45	CES1P1 variant â^'816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. European Journal of Clinical Pharmacology, 2016, 72, 681-687.	1.9	11
46	Carboxylesterase 1-Mediated Drugâ€"Drug Interactions between Clopidogrel and Simvastatin. Biological and Pharmaceutical Bulletin, 2015, 38, 292-297.	1.4	22
47	An ex vivo approach to botanicalâ€"drug interactions: A proof of concept study. Journal of Ethnopharmacology, 2015, 163, 149-156.	4.1	7
48	The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenetics and Genomics, 2014, 24, 381-386.	1.5	13
49	Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study. Clinical Pharmacology and Therapeutics, 2014, 96, 713-722.	4.7	23
50	The Effects of Milk Thistle (Silybum marianum) on Human Cytochrome P450 Activity. Drug Metabolism and Disposition, 2014, 42, 1611-1616.	3.3	46
51	Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation. European Journal of Clinical Pharmacology, 2013, 69, 733-734.	1.9	13
52	Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 648-654.	1.3	9
53	Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 665-672.	2.5	160
54	An Assessment of Pharmacokinetics and Antioxidant Activity of Free Silymarin Flavonolignans in Healthy Volunteers: A Dose Escalation Study. Drug Metabolism and Disposition, 2013, 41, 1679-1685.	3.3	71

#	Article	IF	Citations
55	Limitations of In Vitro Assessments of the Drug Interaction Potential of Botanical Supplements. Planta Medica, 2012, 78, 1421-1427.	1.3	31
56	A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants. Pharmacogenetics and Genomics, 2012, 22, 215-218.	1.5	12
57	A sensitive LCâ€“MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 1-9.	2.3	41
58	Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacological Research, 2012, 65, 491-496.	7.1	51
59	A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples. Biomedical Chromatography, 2012, 26, 1364-1370.	1.7	8
60	Prediction and In Vitro Evaluation of Selected Protease Inhibitor Antiviral Drugs as Inhibitors of Carboxylesterase 1: A Potential Source of Drug-Drug Interactions. Pharmaceutical Research, 2012, 29, 972-982.	3.5	27
61	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatric Disease and Treatment, 2011, 7, 501.	2.2	3
62	Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatographyâ€“tandem mass spectrometry: Application to human ethanol interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 783-788.	2.3	34
63	Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: Potential sources of metabolic drug interactions. Toxicology, 2010, 270, 59-65.	4.2	46
64	Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. Journal of Neurochemistry, 2010, 114, 142-149.	3.9	34
65	Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants. Drug Metabolism and Disposition, 2009, 37, 264-267.	3.3	75
66	Berberine promotes glucagon-like peptide-1 (7â€“36) amide secretion in streptozotocin-induced diabetic rats. Journal of Endocrinology, 2009, 200, 159-165.	2.6	101
67	Age- and Sex-Related Expression and Activity of Carboxylesterase 1 and 2 in Mouse and Human Liver. Drug Metabolism and Disposition, 2009, 37, 1819-1825.	3.3	83
68	Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochemical Pharmacology, 2009, 77, 1266-1272.	4.4	64
69	Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophrenia Research, 2009, 110, 90-94.	2.0	35
70	Enantiospecific gas chromatographicâ€“mass spectrometric analysis of urinary methylphenidate: Implications for phenotyping. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 140-149.	2.3	19
71	Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis. American Journal of Human Genetics, 2008, 82, 1241-1248.	6.2	202
72	Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance Protein. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 336-341.	2.5	51

#	Article	IF	Citations
73	Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. European Journal of Pharmacology, 2008, 578, 148-158.	3.5	30
74	Sertraline and Its Metabolite Desmethylsertraline, but not Bupropion or Its Three Major Metabolites, Have High Affinity for P-Glycoprotein. Biological and Pharmaceutical Bulletin, 2008, 31, 231-234.	1.4	57
75	Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In Vitro. Neuropsychopharmacology, 2007, 32, 757-764.	5.4	84
76	Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behavioural Pharmacology, 2007, 18, 39-51.	1.7	42
77	Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice. Journal of Neuroscience, 2007, 27, 8816-8825.	3.6	66
78	Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 846, 351-354.	2.3	29
79	A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 91-95.	2.3	32
80	Population pharmacokinetic analysis of drugâ€“drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology, 2006, 183, 490-499.	3.1	43
81	Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology, 2006, 187, 415-423.	3.1	110
82	Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 850-857.	2.5	157
83	THE ROLE OF THE POLYMORPHIC EFFLUX TRANSPORTER P-GLYCOPROTEIN ON THE BRAIN ACCUMULATION OF d-METHYLPHENIDATE AND d-AMPHETAMINE. Drug Metabolism and Disposition, 2006, 34, 1116-1121.	3.3	19
84	Pharmacokinetics of Olanzapine After Single-Dose Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of an Orally Disintegrating Tablet in Normal Volunteers. Journal of Clinical Pharmacology, 2006, 46, 164-171.	2.0	53
85	Reversal of P-Glycoprotein Mediated Multidrug Resistance in K562 Cell Line by a Novel Synthetic Calmodulin Inhibitor, E6. Biological and Pharmaceutical Bulletin, 2005, 28, 1974-1978.	1.4	20
86	Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sciences, 2004, 75, 1313-1322.	4.3	91
87	Effect of E6, a novel calmodulin inhibitor, on activity of P-glycoprotein in purified primary cultured rat brain microvessel endothelial cells. Acta Pharmacologica Sinica, 2003, 24, 1143-9.	6.1	11